Melogliptin
Phase III
A DP-IV inhibitor potentially for treatment of type II diabetes.
EMD-675992; GRC-8200
CAS No. 868771-57-7
4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile
4(S)-Fluoro-1-[2-[(1R,3S)-3-(1H-1,2,4-triazol-1-ylmethyl)cyclopentylamino]acetyl]pyrrolidine-2(S)-carbonitrile
4(S)-Fluoro-1-[2-[(1R,3S)-3-(1H-1,2,4-triazol-1-ylmethyl)cyclopentylamino]acetyl]pyrrolidine-2(S)-carbonitrile
Note………The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent
MELOGLIPTIN
![]()
GRC-8200, a dipeptidyl peptidase IV inhibitor (DPP-IV), is currently undergoing phase II clinical trials at Glenmark Pharmaceuticals and Merck KGaA for the treatment of type 2 diabetes. In 2006, the compound was licensed by Glenmark Pharmaceuticals to Merck KGaA in Europe, Japan and N. America for the treatment of type 2 diabetes, however, these rights were reaquired by Glenmark in 2008.
ALTERNATE……….![str1]()
![str1]()
SEE..http://apisynthesisint.blogspot.in/2015/12/melogliptin.html
See more at: http://organicsynthesisinternational.blogspot.in/p/gliptin-series-22.html
see all gliptins……….http://organicsynthesisinternational.blogspot.in/p/gliptin-series-22.html
DISCLAIMER…….The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent
/////////
Filed under: DIABETES, GLENMARK, glenmark, Phase3 drugs, Uncategorized Tagged: DIABETES, EMD-675992, GLENMARK, GRC-8200, melogliptin, PHASE 3
